Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Diabetologia

• Publication date

  1998-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s001250051089PMID 9867210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advanced Glycation End Products-driven Angiogenesis in Vitro

  1997influential reference
• Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells.

  1996cited by this paper
• Elevated Cyclic AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells and Endothelial Cells*

  1996influential reference
• PAI-1 reduction after treatment with glutathione in NIDDM

  1996cited by this paper
• Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture

  1996cited by this paper
• Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin‐producing ability of endothelial cells through interactions with their receptors

  1996influential reference
• Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy.

  1995cited by this paper
• Vascular aldosterone : biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells

  1995cited by this paper
• Possible Participation of Autocrine and Paracrine Vascular Endothelial Growth Factors in Hypoxia-induced Proliferation of Endothelial Cells and Pericytes (*)

  1995influential reference
• 3. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells

  1994cited by this paper
• Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.

  1994cited by this paper
• Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.

  1994cited by this paper
• Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells.

  1994cited by this paper
• Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes.

  1993cited by this paper
• Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells.

  1993cited by this paper
• Immunochemical detection of advanced glycosylation end products in vivo.

  1992cited by this paper
• Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.

  1992cited by this paper
• The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review.

  1992cited by this paper
• Increased Expression of Tissue Plasminogen Activator and Its Inhibitor and Reduced Fibrinolytic Potential of Human Endothelial Cells Cultured in Elevated Glucose

  1992cited by this paper
• Role of protein kinase C and cyclic adenosine monophosphate in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and platelet-derived growth factor mRNA levels in human endothelial cells. Possible involvement of proto-oncogenes c-jun and c-fos.

  1991cited by this paper
• Purification and characterization of tissue plasminogen activator secreted by human embryonic lung diploid fibroblasts, IMR-90 cells.

  1991cited by this paper
• Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.

  1991cited by this paper
• Chronic Diabetic Complications and Tissue Glycosylation: Relevant Concern for Diabetes-Prone Black Population

  1990cited by this paper
• Tissue Plasminogen Activator Inhibition in Diabetes Mellitus

  1989cited by this paper
• Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells.

  1988influential reference
• Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

  1988cited by this paper
• Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus

  1988cited by this paper
• Plasminogen Activation in Diabetes mellitus

  1988cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns.

  1987cited by this paper
• Nonenzymatic glucosylation as a contributing factor to defective fibrinolysis in diabetes mellitus.

  1986cited by this paper
• Postoperative Changes in the Plasmatic Levels of Tissue-Type Plasminogen Activator and Its Fast-Acting Inhibitor - Relationship to Deep Vein Thrombosis and Influence of Prophylaxis

  1985cited by this paper
• The human urokinase-plasminogen activator gene and its promoter.

  1985cited by this paper
• Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells.

  1985cited by this paper
• Plasminogen activator inhibitor in the blood of patients with coronary artery disease.

  1985cited by this paper
• Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors.

  1984cited by this paper
• Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.

  1984cited by this paper
• Restoration of Prostacyclin/Thromboxane A2 Balance in the Diabetic Rat: Influence of Dietary Vitamin E

  1982cited by this paper
• Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin.

  1981cited by this paper
• The biochemistry of the complications of diabetes mellitus.

  1981cited by this paper
• Circulating prostacyclin may be reduced in diabetes.

  1979cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper
• Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

  1978cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• [Eye and the diabetes mellitus].

  1971cited by this paper
• Studies of retinal vascular patterns. I. Normal architecture.

  1960cited by this paper

• The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases

  2024cites this paper
• Role of Uremic Toxins in Vascular Inflammation Associated with Chronic Kidney Disease

  2024cites this paper
• An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition

  2024cites this paper
• Relationships between advanced glycation end products (AGEs), vasoactive substances, and vascular function

  2022cites this paper
• Involvement of RAGE and Oxidative Stress in Inflammatory and Infectious Skin Diseases

  2021cites this paper
• Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World

  2021cites this paper
• Contribution of RAGE axis activation to the association between metabolic syndrome and cancer

  2021cites this paper
• Advanced glycation end-products and their relationship with complications of Diabetes Mellitus

  2021cites this paper
• antioxidants Involvement of RAGE and Oxidative Stress in Inflammatory and Infectious Skin Diseases

  2021cites this paper
• Effects of Exogenous Dietary Advanced Glycation End Products on the Cross-Talk Mechanisms Linking Microbiota to Metabolic Inflammation

  2020cites this paper
• Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases

  2020cites this paper
• A role for mast cells in geographic atrophy

  2020cites this paper
• Influences of advanced glycosylation end products on the inner blood-retinal barrier in a co-cultural cell model in vitro

  2020cites this paper
• Influences of advanced glycosylation end products on the inner blood–retinal barrier in a co-culture cell model in vitro

  2020cites this paper
• AGE–RAGE Stress in the Pathophysiology of Pulmonary Hypertension and its Treatment

  2019cites this paper
• Effect of reducing dietary advanced glycation end products on obesity-associated complications: a systematic review.

  2019cites this paper
• A Review on Study of Anti-Diabetic Activity of Some Herbal Plants in Experimentally Induced Diabetic Rats

  2019cites this paper
• Advanced Glycation End Products: A Potential Contributor of Oxidative Stress for Cardio-Vascular Problems in Diabetes

  2019cites this paper
• Adipose-derived Stem Cells Attenuates Diabetic Osteoarthritis via Inhibition of Glycation-mediated Inflammatory Cascade

  2019cites this paper
• Proteomic study of endothelial dysfunction induced by AGEs and its possible role in diabetic cardiovascular complications.

  2018cites this paper
• Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging

  2018cites this paper
• Diabetes and Advanced Glycation End Products

  2018cites this paper
• Role of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis

  2018cites this paper
• Faculteit Geneeskunde en Levenswetenschappen School voor Levenswetenschappen master in de biomedische wetenschappen

  2018cites this paper
• Impact of Experimental Hyperglycemia on the Discrete Parts of the Nervous System in Albino Rats – A Histomorphological Study

  2018cites this paper
• Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes

  2017cites this paper
• Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

  2017cites this paper
• The Role of Hemoglobin A1c as a Biomarker and Risk Assessment Tool in Patients Undergoing Non-cardiac and Cardiac Surgical Procedures.

  2017cites this paper
• Sevelamer reduces endothelial inflammatory response to advanced glycation end products

  2017cites this paper
• A comparison of the type IX collagen levels of the intervertebral disc materials in diabetic and non-diabetic patients who treated with lumbar microdiscectomy

  2017cites this paper
• Uremic Toxicity of Advanced Glycation End Products in CKD.

  2016cites this paper
• Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?

  2016cites this paper
• Protective role of sulphoraphane against vascular complications in diabetes

  2016cites this paper
• Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications

  2015cites this paper
• Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus

  2015cites this paper
• Oncocalyxone A Functions As an Anti-Glycation Agent In Vitro

  2015cites this paper
• Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE

  2015cites this paper
• Role of receptor for advanced glycation end products (RAGE) in liver disease

  2015cites this paper
• Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

  2015cites this paper
• Altered Expression of NF-κB and SP1 after Exposure to Advanced Glycation End-Products and Effects of Neurotrophic Factors in AGEs Exposed Rat Retinas

  2015cites this paper
• Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Cancer Risk

  2015cites this paper
• Gly 82 Ser Polymorphism of the Receptor for Advanced Glycation End Products Gene ( RAGE ) and the Endogenous Secretory RAGE ( esRAGE ) and its Association with Diabetic Retinopathy in Type 2 Diabetic Patients

  2015cites this paper
• Relationship between Urinary Pentosidine Concentration and Vascular Complications in Type 2 Diabetic Patients

  2015cites this paper
• Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis

  2015cites this paper
• Endothelial Dysfunction in Metabolic and Vascular Disorders

  2014cites this paper
• Advanced glycation end-products induce endoplasmic reticulum stress in human aortic endothelial cells

  2014cites this paper
• Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling.

  2014cites this paper
• The growth factor effect on endothelial cell dysfunction in the presence of glycated collagen and Abeta peptide: implications for decreased angiogenesis in diabetes and Alzheimer's disease

  2014cites this paper
• Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets

  2014cites this paper
• Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis

  2014cites this paper
• Kakkalide ameliorates endothelial insulin resistance by suppressing reactive oxygen species‐associated inflammation (葛花苷通过抑制活性氧相关的炎症改善内皮细胞胰岛素抵抗)

  2013cites this paper
• Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

  2013cites this paper
• Role of N–epsilon- carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus

  2013cites this paper
• Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.

  2013cites this paper
• Polymorphism of the RAGE Affects the Serum Inflammatory Levels and Risk of Ischemic Stroke in a Chinese Population

  2013cites this paper
• Beneficial Effects of Vildagliptin on Retinal Injury in Obese Type 2 Diabetic Rats

  2013cites this paper
• Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells.

  2013cites this paper
• Neurite regeneration in adult rat retinas exposed to advanced glycation end-products and regenerative effects of neurotrophin-4.

  2013cites this paper
• Intérêt du RAGE comme biomarqueur circulant : du sRAGE aux autoanticorps anti-sRAGE

  2013cites this paper
• EFFECT OF NATURAL COCOA POWDER SUPPLEMENTATION ON OXIDATIVE STRESS AND HEMATOLOGICAL INDICES IN HEALTHY GHANAIAN ADULTS

  2013cites this paper
• Advanced glycation end products in diabetes mellitus 11 glycation glycated proteins O 2 AGE protein oxidation reactive dicarbonyls glucose oxidation lipid peroxidation

  2012cites this paper
• Methylglyoxal promotes oxidative stress and endothelial dysfunction.

  2012cites this paper
• Advanced glycation end products increase permeability of brain microvascular endothelial cells through reactive oxygen species-induced vascular endothelial growth factor expression.

  2012cites this paper
• [Glycation of extracellular matrix proteins and its role in atherosclerosis].

  2012cites this paper
• Glucose-dependent Insulinotropic Polypeptide (GIP) Inhibits Signaling Pathways of Advanced Glycation End Products (AGEs) in Endothelial Cells via its Antioxidative Properties

  2012cites this paper
• Protection of Retinal Ganglion Cells and Retinal Vasculature by Lycium Barbarum Polysaccharides in a Mouse Model of Acute Ocular Hypertension

  2012cites this paper
• Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.

  2012cites this paper
• The effects on markers of cellular stress and RAGE splicing in cellular models and in subjects receiving dietary CLA supplementation

  2012cites this paper
• Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.

  2011cites this paper
• RAGE biology, atherosclerosis and diabetes.

  2011cites this paper
• Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level.

  2011cites this paper
• Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.

  2011cites this paper
• Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.

  2011cites this paper
• Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy.

  2011cites this paper
• Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.

  2011cites this paper
• Pathogenesis of Microvascular Complications

  2010cites this paper
• Pathophysiology of the proatherothrombotic state in the metabolic syndrome.

  2010influential citation
• RAGE: a multi-ligand receptor unveiling novel insights in health and disease.

  2010cites this paper
• Die Bedeutung von AGEs und ROS bei Atherosklerose

  2010cites this paper
• Oxidative stress and diabetic complications.

  2010cites this paper
• Chronic Diabetic Complications: Endothelial Cells at the Frontline

  2010cites this paper
• AGEs activate mesangial TGF-b –Smad signaling via an angiotensin II type I receptor interaction

  2010cites this paper
• Serum glucose level at hospital admission correlates with left ventricular systolic dysfunction in nondiabetic, acute coronary patients: the Hellenic Heart Failure Study

  2010cites this paper
• Oxidative Stress and Diabetic Complications Epigenetics : Mechanisms and Implications for Diabetic Complications

  2010cites this paper
• Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention

  2010cites this paper
• Anti-vasopermeability effects of PEDF in retinal-renal disorders.

  2010cites this paper
• Involvement of aldosterone-mineralocorticoid receptor system in advanced glycation end product (AGE)-elicited plasminogen activator inhibitor-1 (PAI-1) expression in diabetes.

  2010cites this paper
• [The role of AGEs and ROS in atherosclerosis].

  2010cites this paper
• PLC/CAMK IV-NF-kappaB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells.

  2010cites this paper
• Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression.

  2010cites this paper
• Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model.

  2009cites this paper
• Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading.

  2009cites this paper
• Pathophysiology of Diabetic Nephropathy: Involvement of Multifaceted Signalling Mechanism

  2009cites this paper
• AGE, ALE, RAGE, and Disease A Food Perspective

  2009cites this paper
• Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation

  2009cites this paper
• Aminoacid support in the prevention of diabetes and diabetic complications.

  2009cites this paper
• Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.

  2009cites this paper
• Investigação dos polimorfismos -429T>C e -374T>A da região promotora do gene rage com marcadores de risco para doença arterial coronariana em indivíduos com Diabetes Mellitus tipo 1

  2008cites this paper
• Advanced glycation end products and cardiovascular disease.

  2008cites this paper
• Skin autofluorescence in diabetes mellitus

  2008cites this paper